Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Fourth Quarter and Year 2014 Results
Revenue Increased 115% Year Over Year to $38.6 Million MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year
View HTML
Toggle Summary Intersect ENT to Present at the 27th Annual ROTH Conference
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the 27 th Annual ROTH Conference . The presentation is scheduled for 3:00 p.m. PT on Tuesday , March 10, 2015 , at the Ritz-Carlton in
View HTML
Toggle Summary Intersect ENT to Announce Fourth Quarter and Year 2014 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for the fourth quarter and year 2014 on February 26, 2015 .
View HTML
Toggle Summary Intersect ENT to Present at Leerink Partners Global Healthcare Conference 2015
MENLO PARK, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will present an overview of the company's business at the Leerink Partners 2015 Global Healthcare Conference. The presentation is scheduled for 1:25 p.m.
View HTML
Toggle Summary Intersect ENT Announces Preliminary 2014 Financial Results
MENLO PARK, Calif. , Jan. 12, 2015 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that it expects to report revenue for the fourth quarter of 2014 in the range of $13.2 to
View HTML
Toggle Summary Intersect ENT Announces Changes to Board of Directors
MENLO PARK, Calif., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the resignations of Rick Anderson, PTV Healthcare Capital, and Mark Fletcher, Medtronic,
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2014 Results
Third Quarter Revenue Increased 113% Year-Over-Year to $9.1 Million
View HTML
Toggle Summary Intersect ENT Added to Russell 2000 Index
MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Intersect ENT (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the Company has been added to the Russell 2000 ® index, effective as of the close of
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2014 Results
Second Quarter Revenue Increased 118% Year-Over-Year to $8.6 Million
View HTML
Toggle Summary Intersect ENT Announces Closing of its Initial Public Offering
MENLO PARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Intersect ENT, Inc. (Nasdaq:XENT), a commercial drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its initial public offering of 5,750,000 shares of
View HTML